Biomarker Profile for Prediction of Response to SMAC Mimetic Monotherapy in Pediatric Precursor B-Cell Acute Lymphoblastic Leukemia. Biomarker Profile for Prediction of Response to SMAC Mimetic Monotherapy in Pediatric Precursor B-Cell Acute Lymphoblastic Leukemia

SMAC Mimetics (SMs) are currently being evaluated in clinical trials. Biomarkers are urgently needed for prediction of patient response to SMs. This study identified a characteristic gene expression pattern of SM sensitivity suitable for upfront identification of samples with high sensitivity to SMs. Overall design: Differentially regulated genes between 8 SM-sensitive and 6 SM-insensitive BCP-ALL samples were identified using Human Genome U133 Plus 2.0 Arrays.